NSPKU statement on the use of Kuvan in Scotland

The Scottish Medicines Consortium (SMC) has today announced that they have rejected the submission for the routine funding of Kuvan in Scotland.

The NSPKU is very disappointed by this decision. Kuvan is used as a treatment for PKU in the overwhelming majority of EU countries and it is unacceptable that patients in Scotland continue not to have access to this treatment.

The NSPKU will continue to work with Scottish MPs and MSPs to call for fair access to Kuvan in Scotland and for a better appraisal system for rare disease medicines in Scotland. NSPKU will also call on BioMarin (the license holder for Kuvan) to make a new submission to the SMC at the earliest possible opportunity.

13th August 2018